If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
IPO today
Upcoming IPO
Biofrontera (BFRI)
Marpai (MRAI)
Cingulate, Inc. (CING)
Stronghold Digital Mining, Inc. (SDIG)
Enfusion, Inc. (ENFN)
Portillos Inc. (PTLO)
Winc, Inc. (BEV)
The Vita Coco Company, Inc. (COCO)
P10, Inc. (PX)
Ventyx Biosciences, Inc. (VTYX)
Winc, Inc. (WBEV)
Runway Growth Finance Corp (RWAY)
Aris Water Solutions, Inc. (ARIS)
Minerva Surgical, Inc (UTRS)
Informatica Inc. (INFA)
Xilio Therapeutics, Inc. (XLO)
Arteris, Inc. (AIP)
Priced IPO
Mink Therapeutics, Inc. (INKT)
Paragon 28, Inc. (FNA)
Ihs Holding Limited (IHS)
Gitlab Inc. (GTLB)
Lucid Diagnostics, Inc. (LUCD)
Healthcare Triangle (HCTI)
AvidXchange (AVDX)
Cognition Therapeutics, Inc. (CGTX)
Isoplexis Corporation (ISO)
Pyxis Oncology, Inc. (PYXS)
Life Time Group Holdings, Inc. (LTH)
Theseus Pharmaceuticals, Inc. (THRX)
Tricon Residential (TCN)
Volcon (VLCN)
Nuvei (NVEI)
Tdcx, Inc. (TDCX)
First Watch Restaurant Group, Inc. (FWRG)
Exscientia Limited (EXAI)
Warby Parker (WRBY)
Olaplex Holdings Inc. (OLPX)
More companies

Mink Therapeutics, Inc. (INKT)

Sector - Healthcare

Price chart

Return from IPO

Company News

IPO Profile

About company

They are a clinical stage biopharmaceutical company pioneering the discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells are a distinct T cell population that combine durable memory responses with the rapid cytolytic features of natural killer (NK) cells. Their proprietary platform is designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. As such, they believe that their approach represents a highly versatile application for therapeutic development in cancer and immune diseases. They are leveraging their platform and manufacturing capabilities to develop a wholly owned or exclusively licensed pipeline of both native and engineered iNKT cells, and anticipate having multiple clinical and preclinical readouts in 2021 and 2022. Their most advanced product candidate, AGENT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy that is currently in multiple Phase 1 clinical trials. They have commenced a Phase 1 clinical trial of AGENT-797 for the treatment of multiple myeloma and expect to report top-line data from this trial in the fourth quarter of 2021. In addition, in August 2021, they received FDA clearance to initiate a clinical study for the treatment of solid tumors, which they intend to advance as their lead indication for AGENT-797 as a monotherapy and in combination with checkpoint inhibitors.
Pharmaceutical Preparations
Employees Founded
31 2017


Address: 149 Fifth Avenue Suite 500 New York, Ny 10010

Telephone: 212-994-8250

Web page:

IPO information

First Trade Date 10/15/2021
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
Share prices ($)

Shares & Volumes

Shares Initial (MM) 4
Shares Revised (MM) 3.33
Expected offer amount (MM) $52
Realized offer amount(MM) $39.96

Financial Data (last reporting year)

Market Cap (MM) $427.18
Revenues (MM) $0
Net Income (Loss) (MM) $-17.76


What do you think will happen with the INKT share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: Evercore ISI

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Evercore ISI/ William Blair
B.Riley Securities/ Baird

Sector: Healthcare

Tweets about $INKT

Tweets volume:

RT volume:


Google Trends Stats